In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Hold rating on Chimerix (CMRX), with a price target of $6. The company’s shares closed yesterday at $3.49, close to its 52-week low of $3.11.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.7% and a 50.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Allogene Therapeutics Inc.
Currently, the analyst consensus on Chimerix is a Moderate Buy with an average price target of $8.
Based on Chimerix’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.61 million. In comparison, last year the company had a GAAP net loss of $17.31 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox.
Read More on CMRX: